
Pharma Industry has increased R&D investments



Lääkete **2** llisuus

Source: Pharma Indsutry Finland 2019

Investments are expected to increase in the coming two years



Pharma companies expect to invest approximately 32 millions more to Finland in coming two years.

Source: Pharma Indsutry Finland 2019

Lääkete**Q**llisuus





Diabetes medicines Cardiovascular medicines Genitourinarysystem and sex hormones medicines Cancer medicines Nervoussystem medicines Other


In Finland most of the clinical trials are conducted with cancer medicines but the most of the patients are in cardio-vascular trials.

Source: Pharma Indsutry Finland 2019

Lääkete**2**llisuus

Number of trials and patients in 2018

medicine and vaccine studies




There were 191 medicine and vaccine studies, in which approximately 7 500 patients participated in Finland in 2018.

Source: Pharma Industry Finland 2019

Lääkete**Q**llisuus


Clinical trials in the most significant ATC-groups in Finland in 2018



Source: Pharma Indsutry Finland 2019

Lääkete**Q**llisuus


Trial subjects in different indication areas without vaccine studies in Finland in 2018



Lääkete **2** llisuus

Source: Pharma Industry Finland 2019


The number of clinical trial notified to Fimea



Lääkete **2** llisuus

Source: Fimea 2019

How the number of registry studies is going change in the coming two years



Investments will increase

■ No changes in investments

■ Investments will decrease

I don't know

Registry studies are typically based on health registries or other national registries. The studies are based on large samples and big data sets. Typically one cannot identify trial subjects in the data. The studies might be a request of authorities or company need to follow the actual use of their products.

Source: Pharma Indsutry Finland 2019

Lääkete^Qllisuus